The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Open accessAbstract
Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases expressed on the cell membrane that play crucial roles in both developmental and adult cells. Dysregulation of FGFRs has been implicated in a wide variety of cancers, such as urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma. Due to their functional importance, FGFRs have been considered as promising drug targets for the therapy of various cancers. Multiple small molecule inhibitors targeting this family of kinases have been developed, and some of them are in clinical trials. Furthermore, the pan-FGFR inhibitor erdafitinib (JNJ-42756493) has recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic or unresectable urothelial carcinoma (mUC). This review summarizes the structure of FGFR, especially its kinase domain, and the development of small molecule FGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., & Mohammadi, M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00073-3 · Cited by 1,199
Evolution of the Fgf and Fgfr gene families
Itoh, N., & Ornitz, D. M. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.08.007 · Cited by 1,096
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Structural basis for fibroblast growth factor receptor activation
Mohammadi, M., Olsen, S. K., & Ibrahimi, O. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.008 · Cited by 735
Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin
Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., & Blundell, T. L. (2000) · Nature · doi:10.1038/35039551 · Cited by 704
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A. C., Abraham, R. T., Ashendel, C. L., Zalkow, L. H., Matter, W. F., Dodge, J. A., & Grindey, G. B. (1994) · PubMed · Cited by 687
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Exploring mechanisms of FGF signalling through the lens of structural biology
Goetz, R., & Mohammadi, M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3528 · Cited by 573
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling
Chen, G., Liu, Y., Goetz, R., Fu, L., Jayaraman, S., Hu, M.-C., Moe, O. W., Liang, G., Li, X., & Mohammadi, M. (2018) · Nature · doi:10.1038/nature25451 · Cited by 487
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., Schmid, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 477
The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis
Razzaque, M. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.196 · Cited by 448
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0699 · Cited by 446
A helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Nogova, L., Sequist, L. V., Perez Garcia, J. M., Andre, F., Delord, J.-P., Hidalgo, M., Schellens, J. H. M., Cassier, P. A., Camidge, D. R., Schuler, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2048 · Cited by 432
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424 · cited 1×
“Although nonselective inhibitors might be clinically beneficial and achieve therapeutic success to some extent, the development of those inhibitors has been restricted due to the undesirable off-target toxicities [80,81].”
BackgroundProlonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 422
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism
Mohammadi, M., Schlessinger, J., & Hubbard, S. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80131-2 · Cited by 370
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Schlessinger, J. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008912 · Cited by 340
FGF signalling: diverse roles during early vertebrate embryogenesis
Dorey, K., & Amaya, E. (2010) · Development · doi:10.1242/dev.037689 · Cited by 335
Perera, T. P. S., Jovcheva, E., Mevellec, L., Vialard, J., De Lange, D., Verhulst, T., Paulussen, C., Van De Ven, K., King, P., Freyne, E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0589 · Cited by 334
Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 313
The (un)targeted cancer kinome
Fedorov, O., Müller, S., & Knapp, S. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.297 · Cited by 292
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., & Mohammadi, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.028 · Cited by 291
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Three-dimensional structure of human basic fibroblast growth factor.
Eriksson, A. E., Cousens, L. S., Weaver, L. H., & Matthews, B. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3441 · Cited by 284
Autophosphorylation of FGFR1 Kinase Is Mediated by a Sequential and Precisely Ordered Reaction
Furdui, C. M., Lew, E. D., Schlessinger, J., & Anderson, K. S. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.022 · Cited by 264
Vijayan, R. S. K., He, P., Modi, V., Duong-Ly, K. C., Ma, H., Peterson, J. R., Dunbrack, R. L., & Levy, R. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501603h · Cited by 245
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Lee, S., Choi, J., Mohanty, J., Sousa, L. P., Tome, F., Pardon, E., Steyaert, J., Lemmon, M. A., Lax, I., & Schlessinger, J. (2018) · Nature · doi:10.1038/nature25010 · Cited by 236
Covalent protein modification: the current landscape of residue-specific electrophiles
Shannon, D. A., & Weerapana, E. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.021 · Cited by 230
Olsen, S. K., Ibrahimi, O. A., Raucci, A., Zhang, F., Eliseenkova, A. V., Yayon, A., Basilico, C., Linhardt, R. J., Schlessinger, J., & Mohammadi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307287101 · Cited by 192
Zhao, G., Li, W.-Y., Chen, D., Henry, J. R., Li, H.-Y., Chen, Z., Zia-Ebrahimi, M., Bloem, L., Zhai, Y., Huss, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0306 · Cited by 189
Self-citationTan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 174
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Joshi, J. J., Coffey, H., Corcoran, E., Tsai, J. J.-Y., Huang, C. L., Ichikawa, K., Prajapati, S., Hao, M., Bailey, S. L., Wu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1865 · Cited by 162
Wang, F., Kan, M., Yan, G.-C., Xu, J.-M., & Mckeehan, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.10231 · Cited by 157
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 156
Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D’Incalci, M., Cavalletti, E., Giavazzi, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2700 · Cited by 148
Bono, F., Smet, F. D., Herbert, C., Bock, K. D., Γεωργιάδου, Μ., Fons, P., Tjwa, M., Alcouffe, C., Ny, A., Bianciotto, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.019 · Cited by 146
Byron, S. A., Chen, H., Wortmann, A., Loch, D. C., Gartside, M. G., Dehkhoda, F., Blais, S. P., Neubert, T. A., Mohammadi, M., & Pollock, P. M. (2013) · Neoplasia · doi:10.1593/neo.121106 · Cited by 141
Sánchez-Heras, E., Howell, F. V., Williams, G. H., & Doherty, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608655200 · Cited by 136
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 135
Herbert, C., Schieborr, U., Saxena, K., Juraszek, J., Smet, F. D., Alcouffe, C., Bianciotto, M., Saladino, G., Sibrac, D., Kudlinzki, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.018 · Cited by 134
Kinase Regulation by Hydrophobic Spine Assembly in Cancer
Hu, J., Ahuja, L. G., Meharena, H. S., Kannan, N., Kornev, A. P., Taylor, S. S., & Shaw, A. S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00943-14 · Cited by 133
Kalyukina, M., Yosaatmadja, Y., Middleditch, M., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019) · ChemMedChem · doi:10.1002/cmdc.201800719 · Cited by 130
Tucker, J. A., Klein, T., Breed, J., Breeze, A. L., Overman, R., Phillips, C., & Norman, R. A. (2014) · Structure · doi:10.1016/j.str.2014.09.019 · Cited by 124
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 121
Understanding the Impact of the P-loop Conformation on Kinase Selectivity
Guimarães, C. R. W., Rai, B. K., Munchhof, M. J., Liu, S., Wang, J., Bhattacharya, S. K., & Buckbinder, L. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200153c · Cited by 120
Farrell, B., & Breeze, A. L. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180004 · Cited by 118
Weiss, A., Adler, F., Buhles, A., Stamm, C., Fairhurst, R. A., Kiffe, M., Sterker, D., Centeleghe, M., Wartmann, M., Kinyamu-Akunda, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1291 · Cited by 113
Cheetham, G. M. T., Charlton, P., Golec, J. M. C., & Pollard, J. R. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.004 · Cited by 107
Gowardhan, B., Douglas, D. A., Mathers, M. E., McKie, A. B., McCracken, S. R., Robson, C. N., & Leung, H. Y. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602274 · Cited by 105
Brameld, K. A., Owens, T. D., Verner, E. J., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00360 · Cited by 104
Lu, X., Chen, H., Patterson, A. V., Smaill, J. B., & Ding, K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01531 · Cited by 104
Sequence Determinants of a Specific Inactive Protein Kinase Conformation
Hari, S. B., Merritt, E. A., & Maly, D. J. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.05.005 · Cited by 97
Hierro, C., Rodon, J. A., & Tabernero, J. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.027 · Cited by 95
The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition
Kalinina, J., Dutta, K., Ilghari, D., Beenken, A., Goetz, R., Eliseenkova, A. V., Cowburn, D., & Mohammadi, M. (2012) · Structure · doi:10.1016/j.str.2011.10.022 · Cited by 94
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Weisberg, E., Choi, H. G., Ray, A., Barrett, R., Zhang, J., Sim, T., Zhou, W., Seeliger, M. A., Cameron, M. D., Azam, M., et al. (2010) · Blood · doi:10.1182/blood-2009-11-251751 · Cited by 68
Ho, H. K., Yeo, A. H. L., Kang, T. S., & Chua, B. T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.021 · Cited by 66
Novel Mutations in Neuroendocrine Carcinoma of the Breast
Ang, D. C., Ballard, M., Beadling, C., Warrick, A., Schilling, A., O’Gara, R., Pukay, M., Neff, T. L., West, R. B., Corless, C. L., et al. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pdm.0b013e3182a40fd1 · Cited by 62
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
Wu, D., Guo, M., Min, X., Dai, S., Li, M., Tan, S., Li, G., Chen, X., Ma, Y., Li, J., et al. (2018) · Chemical Communications · doi:10.1039/c8cc07546h · Cited by 61
Self-citationKarkera, J. D., Cardona, G. M., Bell, K., Gaffney, D. S., Portale, J. C., Santiago-Walker, A., Moy, C. H., King, P., Sharp, M. C., Bahleda, R., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0518 · Cited by 60
The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT
Ryan, M. R., Sohl, C. D., Luo, B., & Anderson, K. S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0429 · Cited by 58
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
Zhou, Z. M., Chen, X., Fu, Y., Zhang, Y., Dai, S., Li, J., Chen, L., Xu, G., Chen, Z., & Chen, Y. (2019) · Chemical Communications · doi:10.1039/c9cc02052g · Cited by 58
Self-citationHuang, Z., Tan, L., Wang, H., Liu, Y., Blais, S. P., Deng, J., Neubert, T. A., Gray, N. S., Li, X., & Mohammadi, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500674s · Cited by 54
Fairhurst, R. A., Knöpfel, T. F., Leblanc, C., Buschmann, N., Gaul, C., Blank, J., Galuba, I., Trappe, J., Zou, C., Voshol, J., et al. (2017) · MedChemComm · doi:10.1039/c7md00213k · Cited by 49
Knöpfel, T. F., Furet, P., Mah, R., Buschmann, N., Leblanc, C., Ripoche, S., Graus-Porta, D., Wartmann, M., Galuba, I., & Fairhurst, R. A. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00485 · Cited by 49
Weiner, H. L., & Zagzag, D. (2000) · Cancer Investigation · doi:10.3109/07357900009012194 · Cited by 38
Blackwell, C., Sherk, C. S., Fricko, M., Ganji, G., Barnette, M. S., Hoang, B. Q., Tunstead, J. R., Skedzielewski, T., Alsaid, H., Jucker, B. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9515 · Cited by 38
c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation
Duan, Y., Chen, L., Chen, Y., & Fan, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106225 · Cited by 37
Self-citationWu, D., Guo, M., Philips, M. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162491 · Cited by 36
Influence of Heparin Mimetics on Assembly of the FGF·FGFR4 Signaling Complex
Saxena, K., Schieborr, U., Anderka, O., Duchardt, E., Elshorst, B., Gande, S. L., Janzon, J., Kudlinzki, D., Sreeramulu, S., Dreyer, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.095109 · Cited by 34
Kinetic mechanism and ATP‐binding site reactivity of p38γ MAP kinase
Fox, T., Fitzgibbon, M. J., Fleming, M. A., Hsiao, H.-M., Brummel, C. L., & Su, M. S. S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01488-x · Cited by 28
Biophysical characterization of drug‐resistant mutants of fibroblast growth factor receptor 1
Yoza, K., Himeno, R., Amano, S., Kobashigawa, Y., Amemiya, S., Fukuda, N., Kumeta, H., Morioka, H., & Inagaki, F. (2016) · Genes to Cells · doi:10.1111/gtc.12405 · Cited by 28
Shabani, M., & Hojjat‐Farsangi, M. (2015) · Current Drug Targets · doi:10.2174/1389450116666151001104133 · Cited by 22
Yang, Y., Ye, Q., Jia, Z., & Côté, G. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672410 · Cited by 15
Cited by
Krook, M. A., Reeser, J. W., Ernst, G., Barker, H., Wilberding, M., Li, G., Chen, H.-Z., & Roychowdhury, S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01157-0 · Cited by 363
Pediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
FGFR-TKI resistance in cancer: current status and perspectives
Yue, S., Li, Y., Chen, X., Wang, J., Li, M., Chen, Y., & Wu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01040-2 · Cited by 145
Self-citation
Metadata
- Authors
- Dai, S., Zhou, Z., Chen, Z., Xu, G., & Chen, Y.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-06-18
- Volume
- 8
- Issue
- 6
- Pages
- 614
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2951548994
- Cited by
- 288
- References
- 97
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.